Loading...

RFL RAFAEL HOLDINGS INC Expansion Plans 8-K Filing

RFL

RFL

RAFAEL HOLDINGS INC

(RFL)

2025 8-K

Show Summary

Summary

Product Expansion

Financial Statements

Rights Offerings

Rights Offerings

Rights Offerings

Rights Offerings

Rights Offerings

Merger of Equals

Merger Completion

Shareholder Meeting

Earnings Release

Merger Agreement

Annual Meeting Results

Stock Conversion

Earnings Announcement

Earnings Announcement

Merger Agreement

Management Changes

Earnings Reports

Amendment filing

Earnings Report

Restructuring of Debt and E...

Annual Meeting of Stockholders

Earnings Reports

Earnings Report

Resignation of Director

Change of Control

Earnings Report

Stock Repurchase Program an...

Earnings Release

Departure of CFO

Annual Meeting of Stockholders

Management Change

External Links:

On June 18, 2025, Rafael Holdings announced that its phase 3 study for Trappsol® Cyclo™ to treat Niemann-Pick Disease Type C1 will continue after a favorable review of safety and efficacy data by an independent committee.

AI Assistant

RAFAEL HOLDINGS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.